Statistically significant survival benefit of NOX-A12 + bevacizumab + radiotherapy for glioblastoma patients compared to both standard of care and NOX-A12 + radiotherapy demonstrated by latest...
Vaxcyte, Inc. — VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 — — Following VAX-31 Adult Phase 1/2 Study...